While once deemed to have no medical value, there’s currently a race underway to study and gain FDA approval for the use of psychedelics as a mental health treatment. In this episode of the Business Group on Health Podcast, we speak with Olivia Goldhill, investigative reporter at STAT, about this race and why psychedelic therapy could be the biggest breakthrough in the mental health field in decades. We dive into why now, which products, and what psychedelic therapy approval could mean for patients and employers.

Guest: Olivia Goldhill, Investigative Reporter, STAT

Tags: Business Group on Health, employer sponsored health care, innovation, mental health, mental health treatment, psychedelic therapy
 
Posted in: Audio Podcast, Business Group on Health, Healthcare